Search results

146 results

Sorted by Relevance . Sort by Date

Guidance Remove Guidance filter
Proposed Remove Proposed filter
In consultation Remove In consultation filter
Technology appraisal guidance Remove Technology appraisal guidance filter
COVID-19 rapid guidelines Remove COVID-19 rapid guidelines filter
Diagnostics guidance Remove Diagnostics guidance filter

Tralokinumab for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3823]

Proposed [GID-TA10702] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Eptinezumab for preventing migraine [ID3803]

Proposed [GID-TA10677] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Remimazolam for general anaesthesia [ID3796]

Proposed [GID-TA10679] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency [ID3791]

Proposed [GID-TA10680] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Valoctocogene roxaparvovec for treating severe haemophilia A [ID3806]

Proposed [GID-TA10682] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Baloxavir marboxil for influenza prophylaxis in people aged 12 and over [ID3793]

Proposed [GID-TA10684] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Baloxavir marboxil for treating influenza in people at high risk of complications [ID3794]

Proposed [GID-TA10683] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Rivoceranib for treating unresectable or advanced gastric or gastro-oesophageal junction cancer after 2 or more therapies [ID3819]

Proposed [GID-TA10685] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Ibrutinib with corticosteroids for untreated chronic graft versus host disease [ID3792]

Proposed [GID-TA10722] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Sotagliflozin for treating type 2 diabetes [ID1657]

Proposed [GID-TA10665] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Epicutaneous immunotherapy for treating peanut allergy in children [ID1255]

Proposed [GID-TA10763] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Tofacitinib for treating active ankylosing spondylitis [ID3865]

Proposed [GID-TA10771] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Lenvatinib with pembrolizumab for untreated advanced or unresectable hepatocellular carcinoma [ID3930]

Proposed [GID-TA10811] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Trastuzumab deruxtecan for treating HER2-negative metastatic or unresectable breast cancer after chemotherapy [ID3935]

Proposed [GID-TA10813] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Trastuzumab deruxtecan for treating HER2-mutated unresectable or metastatic non-squamous non-small-cell lung cancer after 1 or more therapies [ID3934]

Proposed [GID-TA10814] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed

Filter (6 in use)

Type 1 selected

Status 2 selected

Last updated

Guidance programme 3 selected

146 results

Tralokinumab for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3823]

Eptinezumab for preventing migraine [ID3803]

Remimazolam for general anaesthesia [ID3796]

Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency [ID3791]

Valoctocogene roxaparvovec for treating severe haemophilia A [ID3806]

Baloxavir marboxil for influenza prophylaxis in people aged 12 and over [ID3793]

Baloxavir marboxil for treating influenza in people at high risk of complications [ID3794]

Rivoceranib for treating unresectable or advanced gastric or gastro-oesophageal junction cancer after 2 or more therapies [ID3819]

Ibrutinib with corticosteroids for untreated chronic graft versus host disease [ID3792]

Sotagliflozin for treating type 2 diabetes [ID1657]

Epicutaneous immunotherapy for treating peanut allergy in children [ID1255]

Tofacitinib for treating active ankylosing spondylitis [ID3865]

Lenvatinib with pembrolizumab for untreated advanced or unresectable hepatocellular carcinoma [ID3930]

Trastuzumab deruxtecan for treating HER2-negative metastatic or unresectable breast cancer after chemotherapy [ID3935]

Trastuzumab deruxtecan for treating HER2-mutated unresectable or metastatic non-squamous non-small-cell lung cancer after 1 or more therapies [ID3934]